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E-mail address: jan.luenemann@uzh.ch (J.D. LünemMultiple sclerosis is a chronic immune-mediated disease of the central nervous system that devel-
ops in young adults with a complex genetic predisposition. Similar to other autoimmune disease,
HLA-DR and -DQ alleles within the HLA class II region on chromosome 6p21 are by far the strongest
risk-conferring genes. Less robust susceptibility effects have been reported for non-MHC related
genetic variants. Improvements in the design of epidemiological studies helped to identify consis-
tent environmental risk-associations such as the increased susceptibility for MS in individuals with
a history of infectious mononucleosis, a symptomatic primary infection with the human c-herpes-
virus Epstein–Barr virus (EBV). Sun exposure and serum vitamin D levels are emerging non-infec-
tious environmental risk factors that may have independent roles. The analysis of environmental
effects will likely expand in the next few years and will allow for the generation of testable hypoth-
eses as to how environmental insults interact with genetic factors to jointly determine the suscep-
tibility to MS. Insights gained from these studies might facilitate the development of prevention
strategies and more effective treatments for MS.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V.
Open access under CC BY-NC-ND license.1. Introduction
Multiple sclerosis (MS) is a chronic immune-mediated disease
of the central nervous system (CNS) characterized by chronic
inﬂammation, demyelination, gliosis, and axonal pathology. Simi-
lar to other common autoimmune diseases, predisposition to MS
is conveyed by immune system associated genes, the strongest risk
factor, HLA-DRB11501, being encoded in the class II major histo-
compatibility (MHC) genomic region [1]. Nevertheless, the high
discordance rate among monozygotic twins as well as the multi-
tude of migration and epidemiological studies that show lati-
tude-dependent north to south gradient of increasing disease
incidence (in the northern hemisphere and the opposite in the
southern) and remarkable differences in risk among people of com-
mon ancestry who migrate to areas of low or high MS prevalence
[2], indicate that MS is a complex multifactorial disease that results
from the intricate, yet not well-understood, interaction of both
genetic and environmental factors.
The quest for identiﬁcation of the potential environmental trig-
gers of MS has been ongoing for decades. Both infectious and non-
infectious agents have been implicated as potential culprits. This
review aims to discuss the environmental factors that have
attracted the most attention in the recent years, including viralcal Societies. Published by Elsevier
mental Immunology, Depart-
interthurerstrasse 190, Swit-
ann).infections, vitamin D, and smoking. Yet, the plethora of controversy
in the ﬁeld makes it difﬁcult to discern one single environmental
factor as a sole trigger of MS. Rather it is more likely that MS sus-
ceptibility is dependent on the elaborate interaction of a variety of
low penetrance genetic factors and environmental agents convey-
ing by themselves low risk, but when combined together resulting
in disease initiation.
2. Genetic factors
Familial aggregation studies consistently showed that the risk
of developing MS is higher for people with MS in the family and
related to the number of genes that are shared with family mem-
bers diagnosed with MS. For instance, a monozygotic twin of an
MS patient has more than 100 times higher risk, compared to the
general population, to develop the disease, while a full-sibling will
have only 20 times and half-siblings only 10 times higher disease
risk [3,4]. Notably, the relationship between familial recurrence
risk and genetic relatedness is non-linear, suggesting that the
susceptibility to develop MS is determined by multiple risk alleles,
each with modest individual effects.
Genome-wide association studies (GWAS) have proved to be a
powerful tool for identifying particular genetic variants associated
with complex diseases and traits. So far, seven GWAS have been
conducted involving almost 10,000 MS patients and 15,000 con-
trols and investigating more than 100,000 single nucleotide poly-
morphisms (SNPs). For more than 3 decades, the MHC class II
region on chromosome 6p21 was the only known MS risk locus.B.V. Open access under CC BY-NC-ND license.
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for MS with an odds ratio of 2–3. Other yet less robust susceptibil-
ity effects were found for other risk loci such as IL7R [5]. Surpris-
ingly, other MS-associated loci like IL2RA, CLEC16, and CD226 are
also know to play role in susceptibility to other autoimmune dis-
ease such as Type 1 diabetes [6]. This overlapping association
points at common defects in essential immune system pathways
that initiate development of autoimmune pathologies. However,
all of these newly identiﬁed MS risk alleles have minor individual
effects with odds ratios lower than 1.3. Moreover, the distinction
whether these susceptibility variants have causative effect or are
inherited due to strong linkage disequilibrium with other yet
unidentiﬁed causal variants remains elusive as so far we do not
understand their functional contribution to MS development.
Although a simple discordance rate might not accurately reﬂect
the contribution of non-genetic or environmental factors since
experimental studies in congenic mice with gradually increasing
numbers of lupus-associated genes have shown that the rate of dis-
ease expression can be titrated through the number of disease-
linked genes under identical environmental inﬂuences [7], the high
discordance rate in monozygotic twins along with changes in risk
that occur with migration indicate that environmental agents play
an essential role in the development of MS.
3. Infectious environmental factors
From the very early days of MS discovery, infections have been
proposed to be the underlying causes of disease initiation. This
assumption led to the development of the ﬁrst FDA-approved
immunomodulatory treatment for MS, Interferon-beta (IFN-b),
known for its antiviral activities. Pierre Marie, a former student
of Jean-Martin Charcot, who ﬁrst described multiple sclerosis as
a clinical entity in 1868 [8], strongly argued that infectious patho-
gens, or more likely combined infections, initiate MS [9]. This
hypothesis was formed during the ‘‘golden era’’ of microbiology
and most likely driven by the excitement over remarkable break-
throughs in the causes and preventions of many infectious diseases
by researches like Louis Pasteur and Robert Koch. A long list of po-
tential infectious triggers of MS has been investigated since then.
The ones that have received most attention during the past years
are discussed below.
4. Epstein–Barr virus
Among the large list of proposed pathogens, including various
herpesviruses, varicella zoster virus, human endogenous
retroviruses, Torque teno virus, Chlamydia and other bacterial
agents, Epstein–Barr virus (EBV) has gained the most notable sci-
entiﬁc interest to date. In the industrialized world, about 50% of
the population acquires EBV between 1 and 5 years of age, while
another large percentage contracts the virus during adolescence
[10]. For about 30–50% of individuals who acquire the virus in
the second decade or later in life, the virus would lead to symp-
tomatic primary infection known as infectious mononucleosis
(IM) that is characterized by glandular fever and massive expan-
sion of virus-speciﬁc T lymphocytes that subside with the resolving
of the infection [10]. Due to improvement of sanitary conditions in
the developed world, it is becoming more common for individuals
to acquire EBV late in life.
Interestingly, compelling evidence support the association of IM
with elevated risk of MS occurrence [11–14]. Based on a recent up-
dated meta-analysis evaluating a total of 18 clinical studies, the
combined relative risk for development of MS after IM was esti-
mated at 2.17 (95% CI 1.97–2.39; P < 1054) [15], while when ana-
lyzed in HLA-DRB115 carriers individuals with history of IM had a
sevenfold increased risk of developing the disease [16].A multitude of epidemiological studies conducted in the past
30 years revealed that MS patients are almost universally, 99.5%,
seropositive for EBV infection, compared to matched healthy con-
trols who have EBV seroprevalence of 94.2% [17]. This difference
in seropositivity is even more pronounced in pediatric MS cases
which have been shown to carry 83% seroprevalence compared
to only 42% in matched healthy controls, while no signiﬁcant dif-
ference was observed for other viruses such as CMV, parvovirus
B19 and varicella zoster [18]. Even though, these observations sug-
gest that EBV plays a role in MS predispositions, EBV infection is
not a prerequisite for disease development since a substantial frac-
tion of children with MS is seronegative for EBV.
Levin et al. investigated blood samples from more than 3 mil-
lion US military personnel taken in continuation of 12 years [19].
The study investigators identiﬁed 69 MS cases and compared them
to matched controls and estimated that a fourfold elevation in anti-
bodies speciﬁc for a mixture of EBV nuclear antigens (EBNA) was
associated with a threefold increase in risk of developing MS. No
such association was observed for CMV antibody titers. EBNA-spe-
ciﬁc antibodies in individuals who developed MS did not differ sig-
niﬁcantly from healthy controls before reaching the age of 20,
while EBNA1 antibodies were two to threefold elevated in MS indi-
viduals at the age of 25 or older suggesting an age-dependent alter-
ation in EBV-speciﬁc antibody titers. No correlation between the
age nor the severity of IM infection and MS risk could be found
[20,21]. Levin et al. speculated that the observed changes in EBV
immunity could be due to concomitant infection with other micro-
organisms or possibly with distinct strains of EBV that alters im-
mune responses to the virus and lead to higher risk of MS.
Similar observations were made by DeLorenze et al. who inves-
tigated serum samples of MS patients up to 30 years before disease
onset and determined a signiﬁcant increase in EBNA1-speciﬁc IgG
titers compared to matched controls, which occurred 15–20 years
prior to disease onset [23]. In patients with clinically isolated syn-
dromes (CIS), antibody responses towards EBNA1 were shown to
be elevated compared to healthy EBV carriers and were predictive
for conversion to clinically deﬁnite MS [24].
Pediatric MS patients were also observed to have increased and
broadened recognition of EBV-encoded nuclear antigen-1 (EBNA1)
antibodies, pointing at an early dysregulation of virus-speciﬁc im-
mune control [25].
EBNA1 is the only EBV-encoded antigen that is consistently ex-
pressed in proliferating EBV-infected memory B cells and CD4+ T
lymphocytes are thought to play an important role in the immune
control of persistent EBV infection. While healthy EBV-carriers
preferentially recognize multiple epitopes within the central part
of the immunogenic domain of EBNA1, MS patients have been
shown to have signiﬁcantly elevated EBNA1-speciﬁc CD4+ T cell
frequencies targeting a much larger number of epitopes within this
region [26]. EBNA1-speciﬁc CD4+ T lymphocytes, but not T cell spe-
ciﬁc for other lytic or latent EBV and CMV peptides, were observed
to have a higher proliferative capacity and enhanced IFNc
secretion.
It is tempting to hypothesize that molecular mimicry enables
EBNA1-speciﬁc T cells to cross-recognize self-autoantigens that
would eventually lead to the initiation and maintenance of autoim-
mune pathologies. In support of this hypothesis, one study showed
that MS patients present with selective elevation of EBNA1-speciﬁc
T cells response that recognize more frequently myelin antigen
than other non-MS-associated autoantigens [27].
Another hypothetical mechanism of how EBV could trigger
autoimmunity is based on its ability to infect and immortalize B
cells by mimicking T-cell help and B-cell receptor signaling [28].
Therefore, it is tempting to speculate that EBV could potentially
infect and immortalize autoreactive B cells that contribute to dis-
ease pathology. Interestingly, the importance of B cells in MS has
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either depleting or interfering with B-cell differentiation are being
tested for their potential efﬁcacy in MS treatment. Moreover, a
study by Seraﬁni et al. reported that postmortem MS brain sam-
ples, but not samples from patients with other inﬂammatory CNS
disease contained considerable numbers of EBV-infected B cells
expressing viral antigens [29]. However, the observations from this
study could not be reproduced by others [30–32].
In conclusion, there is strong epidemiological evidence linking
symptomatic EBV infection with MS development rendering the
virus a major candidate for MS initiation. However, further exper-
iments are needed to elucidate the exact molecular mechanisms
that lead to this association.5. Human herpesvirus-6
Another ubiquitous herpesvirus that has gained relative popu-
larity as potentially associated with MS is the human herpesvi-
rus-6 (HHV-6). It is characterized by phases of latency and
reactivation that bear similarity to relapsing-remitting MS. The
virus has neurotropic potential and was reported to infect oligo-
dendrocytes and microglia cells [33], as well as to establish latency
in CNS tissue which serves as a reservoir of persistent infection
[34]. Another aspect that strengthens the hypothesized involve-
ment of the virus in MS is the observation that primary HHV-6
infection may lead to severe neurological complications such as
encephalitis and epilepsy. Besides being able to infect neural cell,
HHV-6 most commonly establishes infection in T lymphocytes
and supposedly exerts modulatory effects on the immune system
[35].
Various studies in the past 15 years have investigated HHV-6
association with MS. HHV-6 has been detected in serum, CSF as
well as in brain tissue and more predominantly in MS lesions as re-
ported by some studies [36], [37,38], yet contradicted by others
[39].
Besides direct cytopathic effect, other putative mechanisms of
HHV-6 involvement in MS pathology include bystander activation,
and molecular mimicry. The later of which has gained compelling
evidence. Myelin basic protein (MBP), a suspected target of autore-
activity in MS, has been determined to share sequence homology
with HHV-6-encoded U24 protein. Cross-reactive T cells respond-
ing both to MBP and U24 peptides were elevated in MS patients
compared to controls [40].
So far, there is no epidemiological evidence that symptomatic
HHV-6 infection increases the risk for development of MS [41]
and there is no data that would unequivocally support an etiologic
role of HHV-6 in the pathogenesis of MS. However, the neuro- and
lymphotropic potential of virus suggests that bystander reactiva-
tion of HHV-6 could potentially augment CNS inﬂammation.
6. Varicella-zoster virus
Varicella-zoster virus (VZV) is a ubiquitous pathogen that estab-
lishes latency in the dorsal ganglia in about 95% of adults [42]. It is
the causative agent of varicella (chickenpox), and can occasionally
lead to symptomatic reactivation known as zoster [43]. Numerous
epidemiological studies have investigated the link between VZV
and MS, nevertheless, a meta-analysis including 40 reports con-
ducted between 1965-1999 revealed that there is insufﬁcient evi-
dence to support such association [44]. Presence of VZV DNA,
however, has been reported in blood cells [45] and CSF [46] from
relapsing MS patients. Furthermore, Sotelo et al. observed electron
microscopically abundance of viral particles identical to VZV in the
CSF of MS patients during the initial days of disease relapse [47].
However, when Burgoon et al. used identical electron microscopicand PCR techniques they failed to identify presence of viral parti-
cles or DNA in MS CSF or acute MS plaques [48].
The weak epidemiological data and the inconsistency in the
observations render the link between VZV and MS elusive.7. Torque teno virus
Sospedra et al. determined the speciﬁcity of clonally expanded T
cells from CSF of MS patients during exacerbation and observed
that these T cell clones recognized evolutionary conserved argi-
nine-rich motifs of functional protein domains of the orphan virus
Torque teno virus (TTV) [49]. T cell clones resounded to TTV pep-
tides as well as to peptides from other common viruses and self-
antigens. Therefore, the authors speculated that repeated encoun-
ter, both of pathogenic or non-pathogenic infectious agents can
lead to expansion of T cells responsive to conserved protein do-
mains that are able to cross-react with ubiquitous self-antigens.
These observations allude to the conclusion that recurrent infec-
tions with multitude of ubiquitous pathogens rather than one par-
ticular infectious agent could be implicated in the initiation of
reactivity towards self-antigens that may trigger autoimmune
pathologies. However, due to the paucity of data, the relation of
TTV infection and MS remains ill deﬁned.
Not only viruses and bacteria have been linked to MS, but also
parasites. Helminthes are thought to have a protective role in MS
among other autoimmune diseases [50]. The prevalence of hel-
minth infections in countries with high sanitation standards has
lead to the proposition of the hygiene hypothesis stating that reg-
ular exposure to various pathogens is required for the development
of appropriate immune responses. Administration of helminthes
has been shown to ameliorate disease in a mouse model of MS
[51,52]; while one clinical study has shown that when MS patients
developed asymptomatic gastrointestinal infection, they experi-
enced reduction of clinical and radiological MS activity, character-
ized by downmodulation of proinﬂammatory cytokines and
increase in IL-10 and TGF-b production [53]. The role of helminthes
in MS is more extensively discussed in an excellent review by
Fleming [54].8. Non-infectious environmental factors
8.1. Vitamin D
Among the non-infectious environmental triggers, there is a re-
cent upsurge in studies investigating the effects of vitamin D levels
on MS pathogenesis. Vitamin D is a potent immunomodulator
affecting proinﬂammatory pathways [55,56] as well as the number
and activity of regulatory T cells [57]. Epidemiological studies have
shown an increase in MS frequency with increasing distance from
the equator, which inversely correlates with duration and intensity
of sunlight [58–62]. Interestingly, populations situated at high lat-
itudes but having high consumption of vitamin D rich food were
observed to have reduced MS prevalence [63–65], while the risk
of MS incidence decreased with movement from high to low alti-
tudes [2].
Timing of birth has also been implicated as a predictor of MS
susceptibility. A study including a large data set of more than 40
000 MS patients from Sweden, Denmark, Canada and Great Britain
revealed that signiﬁcantly fewer individuals with MS were born in
November, while the incidence of MS was signiﬁcantly higher for
people born in May, indicating an association between prenatal
sunlight and risk of MS. Interestingly, the effect of month of birth
was more evident for familial cases, suggesting a potential gene/
environment interaction [66].
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sure Islam et al. compared sun exposure-related childhood activi-
ties of 79 MS-discordant monozygotic twin pairs [67]. Their
observations conﬁrmed the disease protective effect of sunlight.
Lucas et al. investigated whether past and recent sun exposure
using self-report questionnaires and objective measures of vitamin
D levels are associated with risk of ﬁrst demyelinating event (FDE)
in Australia [68]. They found that higher levels of past, recent, and
accumulated leisure-time sun exposure were each associated with
reduced risk of FDE and that higher serum 25-hydroxyvitamin D
[25(OH)D] levels were independently associated with decreased
FDE risk. Some of the aforementioned interpretations should be
made with caution since, similar to all other questionnaire-based
studies, these results are subjected to recall bias.
To date there is only one longitudinal prospective, nested case-
control study that investigated serum samples from more than 7
million US military personnel and revealed that high serum levels
of 25(OH)D, the metabolite routinely used to evaluate an individ-
ual’s nutritional vitamin D status, are associated with reduced inci-
dence of MS [69].
Moreover, seasonal variations in vitamin D levels inversely cor-
related with gadolinium-enhancing magnetic resonance imaging
lesions [70] and relapse rate [71–74]. In a study investigating ser-
um samples from 267 MS patients, Smolders et al. observed asso-
ciation of low vitamin D levels with both relapse and degree of
disability as measured by EDSS (Expanded Disability Status
Scale)-scoring [75].
In order to investigate better the 25(OH)D availability to the
brain, Holmøy et al. measured 25(OH)D levels in CSF and found
that CSF levels positively correlate with serum vitamin D concen-
trations. However, they could not ﬁnd any signiﬁcant difference
between the levels of the biologically active vitamin D metabolite,
1,25(OH)D in MS patients and controls as well as no association
with relapse or gadolinium-enhanced lesions was determined [76].
An explanation for the beneﬁcial effects of elevated vitamin D
levels could lie in the immunomodulatory potential of the vitamin.
It has been shown to affect and tolerize DCs by suppressing their
pro-inﬂammatory cytokine secretion, expression of maturation
markers, chemotaxis, and capacity to trigger proliferation of anti-
gen-speciﬁc T cells, therefore indirectly inhibiting potentially auto-
reactive T cells [77].
Furthermore, since T cells themselves are described to carry
vitamin D receptors (VDR), direct T cell inhibition is another
hypothesized molecular mechanism of vitamin D effect on MS
pathology. A recent study conducted in mice model of MS reported
that 1,25(OH)D directly inhibits autoreactive T lymphocytes, but
does not alter regulatory T cell frequencies, which bear low levels
of VDR [78].
The exact molecular mechanisms underlying the effect of vita-
min D in MS is still elusive. However, the abundance of studies
pointing at association of low vitamin D concentration and MS
advocate for the beneﬁcial role of vitamin D supplements as pro-
phylactic and/or treatment agents. Clinical studies have indicated
that large doses of 25(OH)D [79] and 1,25(OH)D [80] supplements
are safe and well tolerated by MS patients. Even though disease
progression and activity were not altered by 25(OH)D, the vitamin
supplementation lead to reduction in gadolinium-enhancing le-
sions per patient as described by Kimball et al. [79]. The therapeu-
tic effects of vitamin D supplements are currently being further
investigated.
8.2. Smoking
A history of cigarette smoking has been almost unanimously
associated with increased susceptibility to MS as asserted by a re-
cent meta-analysis reviewing data on 14 studies including morethan 3000 cases and 450 000 controls [81]. The authors, however,
acknowledge that it is highly improbable that this environmental
factor alone account for the worldwide variation in MS prevalence.
A recent study by Hedstrom et al. suggested a signiﬁcant interac-
tion between smoking and two genetic risk factors of MS: presence
of HLA-DRB115 and absence of HLA-A02 [82]. Such interaction
was not observed for non-smokers. Smoking increased the risk of
MS in carriers of both genetic risk factors 2.8-fold, while only
1.4-fold increase was observed for individuals without the suscep-
tibility alleles. The authors suggested that priming of T cell re-
sponses in the lung might contribute to the development of MS
in genetically susceptible individuals.
It remains to be determined whether smoking is indeed an
independent risk factor for MS development. The biological mech-
anisms that would link smoking to the pathogenesis MS are elu-
sive. Nicotine, however, might not be the sole culprit since
studies have shown that use of tobacco snuff does not increase
the risk of MS [83,84].9. Concluding remarks
Collaborative efforts during the past years achieved substantial
progress in deﬁning the genetic architecture, underlying suscepti-
bility to MS. The role of environmental risk factors and their inter-
action with genetic susceptibility alleles are much less well
deﬁned, despite the fact that infections and non-infectious factors
have long been associated with MS development. During the past
decades, many reports that have claimed to identify environmental
MS triggers, and almost universally these observations have later
not withstood scrutiny. What we have learnt from these investiga-
tions is that association studies are inherently vulnerable to con-
founding factors such as selection bias and phenomena like
reverse causality. Therefore, they require an adequate control for
these confounding factors and reproducibility in independent co-
horts. This applies to genetic studies but appears to be even more
important for the analysis of environmental exposures.
Improvements in the design of epidemiological studies helped
to identify consistent environmental risk-associations such as the
increased susceptibility for MS in individuals with a history of
IM, and the analysis of environmental effects will likely expand
in the next few years. A future challenge lies in the design of stud-
ies that use this information to better understand the function of
environmental susceptibility factors and their interaction with ge-
netic risk variants for the development of MS. Insights gained from
these studies could allow for the development of prevention strat-
egies and more effective treatments for MS.References
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